Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-escalation study of single-dose lanreotide PRF in controlled acromegaly
NL-OMON45228Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Jun 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of lanreotide in acromegaly (3 cohorts), sponsored by Ipsen. Primary endpoints: Maximum tolerated dose, Lanreotide pharmacokinetics and 1 more. Started Jun 2015; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON45228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45228.